Chapter 23

Transcatheter Mitral Valve Replacement

The Tendyne Device

Alison Duncan

Alison Duncan

Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, London, UK

Search for more papers by this author
First published: 12 March 2021
Citations: 1

Summary

Mitral regurgitation (MR) is a leading cause of valvular heart disease, but up to half of patients with moderate to severe MR are not referred for conventional mitral valve surgery due to advanced age or multiple comorbidities. Transcatheter mitral valve implantation (TMVI) is an emerging alternative technology, and the only evice with a “Conformite Europeenne” mark and the largest successful experience to date is the Tendyne TMVI device, designed specifically for placement in the native mitral annulus. This chapter reviews the development of the Tendyne TMVI system, preprocedural planning and selection criteria, implantation technique, periprocedural and early clinical outcome, and long-term follow-up and durability. Successful deployment results in complete relief of mitral regurgitation in most cases, with instantaneous and sustained improvements in cardiac physiology and significant immediate and longer-term symptomatic improvement.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.